Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank : PAIN Reports

Journal Logo

Neuropathic: Research Paper

Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank

Baskozos, Georgiosa,*; Hébert, Harry L.b; Pascal, Mathilde M.V.a; Themistocleous, Andreas C.a; Macfarlane, Gary J.c; Wynick, Davidd; Bennett, David L.H.a; Smith, Blair H.b

Author Information
PAIN Reports 8(2):p e1066, March 2023. | DOI: 10.1097/PR9.0000000000001066

1. Introduction

Chronic pain, usually defined as pain lasting for 3 months or more,53 is the leading cause of disability worldwide, when all pain conditions are taken into account, including low back pain, headache disorders, and neck pain.23 Neuropathic pain (NeuP) is a particularly severe form of chronic pain, arising as a direct consequence of a lesion or disease affecting the somatosensory nervous system.52 Examples of common causes of NeuP include diabetes, HIV, and chemotherapy treatment for cancer (causing painful peripheral neuropathies), herpes zoster (causing postherpetic neuralgia), multiple sclerosis, surgery, stroke, and spinal cord injury.12 NeuP is likely to be a major contributor to the global burden of chronic pain.7

From a clinician's perspective, it is important to distinguish NeuP from other forms of pain which arises from actual or threatened damage to non-neural peripheral tissue. NeuP is generally unresponsive to analgesics such as nonsteroidal anti-inflammatory drugs or opioids. Rather, gabapentinoids, tricyclic antidepressants, and serotonin–norepinephrine reuptake inhibitors are recommended as first- and second-line treatments.18 Nonetheless, these medications for NeuP provide greater than 50% pain relief in less than half of people treated. Furthermore, analgesics in general, particularly opioids and gabapentinoids, can potentially cause harm, providing an even greater emphasis on appropriate use.26

To identify NeuP in the community screening tools such as the Douleur Neuropathique en Quatre Questions (DN4),8 Self-Administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS)5 and the painDETECT20 have been developed. These rely on typical symptoms experienced in NeuP including burning, electric shocks, pins and needles, and tingling. Estimates of NeuP in the general population suggest the prevalence is 7% to 10%,28 increasing to around 20% to 30% in people with diabetes.1,2,10,13 Previous studies have also reported greater prevalence of NeuP, as with chronic pain overall, in older people, women, and people from areas of high social deprivation.43

However, because of differences in screening tools used and sample selection biases between studies, there is a large amount of heterogeneity in findings. Reliable information on NeuP prevalence and associated factors is vital for developing prevention and management strategies. The UK Biobank has recently rephenotyped participants for chronic pain, creating, to the best of our knowledge, the largest available cohort for the study of pain, including NeuP. Although not representative of the general population, the size and scale of this cohort provide an ideal platform with which to validate the findings of previous studies and identify novel associations.

2. Methods

This study is reported using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cross-sectional studies (supplementary Table 1, available at https://links.lww.com/PR9/A186).

2.1. Data Set

2.1.1. The UK Biobank cohort

UK Biobank comprises 501,518 volunteers recruited between 2006 and 2010 (at ages 40–69 years) from across Great Britain. It consists of demographic and health data as well as linked biosamples and specialist investigations such as imaging in subgroups.46 A brief assessment of chronic pain was completed by all participants at first assessment, although it did not include validated questionnaires enabling categorisation of chronic pain and differentiation of NeuP from non-neuropathic pain (non-NeuP). The authors B.H.S., D.L.H.B., D.W., and G.J.M. participated in the design of a set of revised UK Biobank pain questionnaires6 between 2017 and 2018. This was based on validated questionnaires already in routine use and as far as possible aligned with established international consortia studying chronic pain such as Generation Scotland41,42 and DOLORisk.27,40 These were designed to focus on the most prevalent causes of chronic pain and associated comorbidities and risk factors, including musculoskeletal pain, NeuP, and headache. The choice of items to include for NeuP was based on international recommendations made for phenotyping in genetic studies.29

2.1.2. Rephenotyping for neuropathic pain

The chronic pain phenotyping survey was sent to all currently active UK Biobank participants in May 2019 who had consented to further electronic contact and had an active email address (n = 335,587).

The pain questionnaires first asked about medical history, based on a list of conditions that commonly lead to chronic pain. These included musculoskeletal conditions such as osteoarthritis and rheumatoid arthritis but also important aetiological factors for NeuP such as diabetes, nerve damage, neuropathy, and postherpetic neuralgia.

Participants were asked to indicate whether they had been suffering from pain for more than 3 months (defined as chronic pain53); if yes, they were asked whether they experienced pain all over the body, and if they answered yes, they were asked to report pain intensity and directed to the American College Of Rheumatology (ACR) questionnaire screening for fibromyalgia.59 If they did not experience pain all over the body, they were directed to a list of body sites, where they indicated the locations in which they had experienced pain in the previous 3 months. They also rated the pain intensity at each location over the past 24 hours, on an 11-point visual analogue scale (VAS). They then identified which of these pains had bothered them most during the previous 3 months. The subsequent pain-related questionnaires asked the participants to complete them regarding their most bothersome pain. Participants completed the self-reported items on the DN4 questionnaire which is a validated tool for NeuP screening based on pain quality.8 The characteristics of the most bothersome pain were captured with bespoke questions based on the Brief Pain Inventory (BPI)—Short Form,11 asking about pain intensity over the previous 24 hours and on average. Participants were asked to rate the relief they obtained from pain medication and how their pain impacted different areas of their lives.

The EQ-5D-5L30 was used to ask about health-related quality of life in more detail; this included a 0 to 100 VAS that represented the participant's health at that time, and an assessment of the extent of limitations experienced in different domains of life (mobility, self-care, usual activities, pain or discomfort, and anxiety and depression).

The presence of peripheral neuropathy in the legs and feet was assessed with the self-complete component of the Michigan Neuropathy Screening Instrument (MNSI),16 for those participants who answered yes to the presence of at least one of the following in the medical history section: cancer pain, diabetes, or nerve damage other than diabetic neuropathy. These conditions are common causes of length-dependent peripheral neuropathy, and symptoms are expected to be present distally. Finally, participants were asked to complete psychosocial questionnaires about depression (Patient Health Questionnaire-9 [PHQ-9]35) and fatigue (Fatigue Severity Scale [FSS]).36

Body mass index (BMI) was calculated from data measured during the initial Assessment Centre visit in 2006 to 2010. Ethnic background, job, and current employment status were also collected at recruitment. Age of participants at the time of completion of the pain phenotyping questionnaires was calculated from the year of birth, collected at recruitment, and the time the questionnaires were completed. Index of Multiple Deprivation was calculated using data from distinct domain of deprivations collected at recruitment. The distinct primary diagnosis, coded using the International Classification of Diseases (ICD-10), was recorded from the participants' hospital inpatient record during 2013 to 2022. Full background information about the follow-up UK Biobank pain questionnaire and the questions included is available at https://biobank.ctsu.ox.ac.uk/crystal/ukb/docs/pain_questionnaire.pdf.

For analysing this study, we divided the cohort into 3 groups:

  • (1) Chronic neuropathic pain (NeuP): participants who reported having pain for more than 3 months AND who scored 3 or more on the DN4, N = 13,744.
  • (2) Chronic non-neuropathic pain (non-NeuP): participants who reported having pain for more than 3 months AND who scored less than 3 on the DN4, N = 62,351.
  • (3) No chronic pain (NoCP): participants who did not report having pain OR whose reported pain had lasted less than 3 months, N = 72,733.

Only fully completed DN4 questionnaires were considered for group allocation. Chronic pain participants with an incomplete DN4 were not classified. A flowchart of the group definition is in supplementary Figure 1, available at https://links.lww.com/PR9/A186.

2.2. Statistical analysis

Data were collected electronically by completion of a structured online questionnaire. As nonwhite ethnic backgrounds were rare in UK Biobank (2.2%), we grouped together all Black, Asian, and Minority ethnicities (BAME) into one group, noting the lack of homogeneity of this group. Of the total UK Biobank cohort, 1.7% were BAME, 0.5% were mixed ethnicity, and the remaining 97.3% were white.

Occupations were encoded according to the Departments of National Statistics Standard Occupational Classification (SOC 2000) major groups. The Index of Multiple Deprivation, a weighted composite score showing relative deprivation, ie, the higher the score the more deprived the individual, was used as a measure of poverty.

To determine differences between groups, we performed 1-way analyses of variance (ANOVA) for normally distributed data or the Kruskal–Wallis test for nonparametric data. These were followed up with Tukey honestly significant difference (HSD) post hoc tests. Associations between groups and categorical variables were tested using the χ2 test and followed up by pairwise Bonferroni-corrected χ2 post hoc tests. Statistical significance cutoff was P value <0.05.

In addition, we performed multivariable modelling using binomial or multinomial, multiple logit regression depending on the number of levels of the dependent variable. Before model fitting, we removed variables with >30% missing values, low variance (ratio cutoff 98/2, unique <10), the least informative variable (ie, lower variance) from highly correlated pairs (Pearson's correlation coefficient >0.8) or those directly measuring pain, missing values were imputed in 20 cycles of multiple imputations by chained equations using the predictive mean matching algorithm. Missing value percentages for all variables are in supplementary Table 2, available at https://links.lww.com/PR9/A186. We considered a set of uncorrelated independent variables that included the EQ5D index, sex, age, job, Index of Multiple Deprivations, and the 3 first principal components of genetic variation and binary tags for self-reported diseases: diabetes, other neuropathy, osteoarthritis, rheumatoid arthritis, cancer pain, carpal tunnel syndrome, chronic postsurgical pain, gout, migraine, and pelvic pain. The genetic variation principal component loadings were downloaded from UK Biobank and were calculated by principal component analysis (PCA) analysis on 101284 single nucleotide polymorphisms (SNPs)..

Model coefficients were aggregated across imputations using Rubin's rules. For the significant model coefficients (1-way ANOVA P value < 0.05), we present odds ratios and the associated 95% confidence intervals.

3. Results

3.1. Demographics and socioeconomic status

Approximately 167,203 participants completed the pain experience phenotyping (response rate 49.8%). There was an overrepresentation of participants who were female, of younger age, lower BMI, and less socially deprived in the group that chose to complete the pain rephenotyping questionnaire compared with the rest of the UK Biobank cohort, regardless of whether they were sent a questionnaire, supplementary Table 3, available at https://links.lww.com/PR9/A186. Approximately 148,828 of the 167,203 (89%) participants had no chronic pain or chronic pain with a fully completed DN4 questionnaire (see Methods). The participants with completed DN4 had the same deprivation levels as those who had not completed the questionnaire, but there were more females, of slightly higher age, and higher BMI than the participants with incomplete DN4, supplementary Table 4, available at https://links.lww.com/PR9/A186. Approximately 13,744 participants reported chronic NeuP; 62,351 participants reported chronic non-NeuP; 72,733 participants reported no chronic pain. The prevalence of NeuP in this cross-sectional cohort was, therefore, 9.2% (13,734/148,828). Age and sex showed weak significant associations with outcome: Participants with NeuP were younger than those with non-NeuP (mean difference [MD] −0.33, 95% confidence interval [CI] −0.5, −0.16), Figure 1A and supplementary Figure 2A, available at https://links.lww.com/PR9/A186. Participants who reported chronic pain, both neuropathic (NeuP) and non-neuropathic (non-NeuP), were more likely to be female than those participants without chronic pain (59% vs 52%), Figure 1B and supplementary Figure 2B, available at https://links.lww.com/PR9/A186. Ethnic background was significantly but weakly associated with outcome, Figure 1C. Approximately 96.7% of participants with NeuP were white British, 97.3% in the total UK Biobank cohort. There was a higher proportion of whites in the non-NeuP (97.7%) vs the other groups, whereas BAME were more likely to report NoCP (1.8%) and NeuP (1.9%) vs non-NeuP (1.4%), supplementary Figure 2C, available at https://links.lww.com/PR9/A186. Body mass index was significantly associated with pain grouping (P value <0.001): BMI was significantly higher in participants with NeuP vs non-NeuP (MD 1.14, 95% CI [1.04, 1.23]) and in participants with non-NeuP vs NoCP (MD 1.86, 95% CI [1.76, 1.96]), supplementary Figure 2D, available at https://links.lww.com/PR9/A186. Both employment status and occupation/job type were significantly but weakly associated with the outcome. People with NeuP were more likely to report that they were “unable to work because of sickness or disability” compared with those with non-NeuP and NoCP, Figure 2A and supplementary Figure 3A, available at https://links.lww.com/PR9/A186. People with NeuP were more likely to work in “elementary occupations”—simple and routine tasks, involving the use of hand-held tools and in some cases considerable physical effort; “process, plant, and machine operatives”—operate and monitor large-scale, industrial machinery and equipment; and “personal service occupations” compared with the other 2 groups, Figure 2B and supplementary Figure 3B, available at https://links.lww.com/PR9/A186. The Index of Multiple Deprivation was significantly associated with the outcome and was higher (consistent with increased deprivation), in people with NeuP vs non-NeuP (MD 2.04, 95% CI [1.76, 2.32]) and in NeuP vs NoCP (MD 2.34, 95% CI [2.06, 2.61]). It was also slightly higher in and non-NeuP vs NoCP (MD 0.3, 95% CI [0.14, 0.46]), supplementary Figure 3C, available at https://links.lww.com/PR9/A186.

Figure 1.:
Demographics of participants with chronic NeuP, non-NeuP, and NoCP. (A) Boxplots show the age of participants when questionnaires were completed for each group. Notched line represents the median. (B) Stacked bar plots show the sex distribution across the 3 groups. (C) Stacked bar plots show the ethnic background distribution across the 3 groups. (D) Boxplots show the BMI of participants across the 3 groups. Omnibus ANOVAs are labelled in the plot and are followed up by t tests between groups. P value <0.001 is coded as ***, P value <0.01 is coded as **. Post hoc tests are shown in supplementary Figure 2, available at https://links.lww.com/PR9/A186. ANOVA, analysis of variance; BAME, Black, Asian, and Minority ethnicities; BMI, body mass index; CP, chronic pain; NeuP, neuropathic pain; NoCP, no chronic pain.
Figure 2.:
Socioeconomic status of participants with chronic NeuP, non-NeuP, and NoCP. (A) Dotplot shows the employment status of participants for each group. The group is colour coded, and the respective percentage is coded in the size of the dot. (B) Dotplot shows the occupation of participants for each group. (C) Boxplots show the Index of Multiple Deprivations across the three groups. Omnibus ANOVAs are labelled in the plot and are followed up by t tests between groups. P value <0.001 is coded as. Post hoc tests are shown in supplementary Figure 3, available at https://links.lww.com/PR9/A186. ANOVA, analysis of variance; CP, chronic pain; NeuP, neuropathic pain; NoCP, no chronic pain.

3.2. Pain rating and quality of life

People with NeuP reported higher pain severity ratings for the self-reported most bothersome pain, Figure 3A. The most bothersome pain in people with NeuP was reported to be in the feet, hands, or legs more frequently, whereas reporting the most bothersome pain was reported to be in the back, hip, knee, stomach, abdomen, or head most frequently by people with non-NeuP, Figure 3B. The quality of life as measured by the EQ5D normalised index was dependent on outcome and was significantly lower in people with NeuP vs NoCP (MD –0.22, 95% CI [−0.23, −0.22]) and non-NeuP vs NoCP (MD –0.14, 95% CI [−0.14, −0.14]), Figure 4A and supplementary Figure 4, available at https://links.lww.com/PR9/A186. The association between NeuP and reduced quality of life was consistent across all body locations Figure 4B. People with NeuP were more likely to have “diseases of the nervous system” than by both the other groups and “certain infectious and parasitic diseases” than people with NoCP, Figure 5 and supplementary Figure 5, available at https://links.lww.com/PR9/A186. People with diabetes, rheumatoid arthritis (RA), or other neuropathy were considered at risk of peripheral neuropathy and have completed the MNSI, Figure 5B. People with NeuP had higher MNSI scores than both NoCP and non-NeuP. Only people with NeuP had a score of 3 and above, which is a reasonable cutoff threshold for peripheral neuropathy, in their interquantile range.

Figure 3.:
Pain rating and location of the most bothersome pain. (A) Boxplots show the pain rating for the self-reported location of the most bothersome pain for both painful groups, NeuP vs non-NeuP. (B) Dotplot shows the frequencies for the self-reported location of the most bothersome pain for the 2 painful groups. Rates are coded in the size of the dot. P value <0.001 is coded as ***. NeuP, neuropathic pain.
Figure 4.:
The impact of pain in quality of life. (A) Boxplots show the EQ5D index across the 3 groups. (B) Boxplots show the EQ-5D index for both painful groups across all locations reported as the ones having the most bothersome pain. Omnibus ANOVAs are labelled in the plot and are followed up by t tests between groups. P value <0.001 is coded as ***, P value <0.01 is coded as **. Post hoc tests are shown in supplementary Figure 4, available at https://links.lww.com/PR9/A186. ANOVA, analysis of variance; CP, chronic pain; NeuP, neuropathic pain.
Figure 5.:
(A) Frequencies of diseases across the 3 groups. The rates are coded in the size of the dot. Group allocation is colour coded. Post hoc tests are shown in supplementary Figure 5, available at https://links.lww.com/PR9/A186. (B) MNSI scores across the 3 groups in participants with diabetes, rheumatoid arthritis, and other neuropathy. P value < 0.001 is coded as ***.ANOVA, analysis of variance; CP, chronic pain; MNSI, Michigan Neuropathy Screening Instrument; NeuP, neuropathic pain.

Focusing on people with chronic pain (both NeuP and non-NeuP), we observed that DN4 scores were significantly associated with the pain severity rating and were higher for participants with higher pain ratings for the most bothersome pain, Figure 6A. The highest DN4 scores were those of participants with the most bothersome pain in the feet and legs, followed by hands and face, Figure 6B. People with pain in both feet had significantly higher DN4 scores than people with pain only in one foot, Figure 6C. Pain severity ratings for the most bothersome location were higher in participants with higher BMI scores (Fig. 7A), lower quality of life (Fig. 7B), and/or who were unable to work because of sickness or disability (Fig. 7C) and slightly higher for among participants with higher deprivation scores (Fig. 7D). Pain in the feet and pain in the leg were moderately associated in participants with NeuP, supplementary Figure 6, available at https://links.lww.com/PR9/A186.

Figure 6.:
Pain rating and DN4 scores. (A) Boxplots show the distribution of pain ratings for the most bothersome locations across DN4 scores for both painful groups. Group is colour coded. (B) Boxplots show the DN4 score for all different locations of self-reported most bothersome pain. (C) DN4 scores for people with and without pain in both feet, Omnibus Kruskall–Wallis tests are labelled in the plot. P value <0.001 is coded as ***. DN4, Douleur Neuropathique en Quatre Questions; NeuP, neuropathic pain.
Figure 7.:
Intensity of pain vs participant characteristics. (A) Boxplots show the distribution BMI for different self-reported pain intensities for the most bothersome location. (B) Boxplots show the EQ5D index across self-reported pain intensities for the most bothersome locations. (C) Frequencies of employment status across self-reported pain intensities for the most bothersome locations. (D) Index of Multiple Deprivations or different self-reported pain intensities for the most bothersome location. Notched lines represent the median. BMI, body mass index.

3.3. Multivariable modelling

In Figure 8, we present the odds ratios (ORs) for the terms that reached significance for the multinomial model with a three-level dependent variable considering no chronic pain as the reference condition. All terms are in supplementary Table 5, available at https://links.lww.com/PR9/A186. Both NeuP and non-neuP were strongly associated with having lower quality of life (assessed using EQ-5D index in which a higher score reflects a higher quality of life). The presence of diabetes increased the OR for NeuP and decreased them for non-NeuP. All other self-reported conditions increased the ORs for both NeuP and non-NeuP but had a larger effect for NeuP. Male participants had lower OR for both NeuP and non-NeuP. In addition, those who were “managers and senior officials” were more likely to report non-NeuP. “Process, plant, and machine operatives” and “skilled trade occupations” increased the odds for NeuP, whereas “professional occupations” decreased the odds for NeuP.

Figure 8.:
Coefficient estimates of the multinomial logit model. Dots represent the exponentiated coefficient estimates, ie, odds ratios, and lines show the 95% confidence interval for all terms with an 1-way ANOVA P value <0.05. Odds ratios are calculated for NeuP and non-NeuP against the reference level NoCP. ANOVA, analysis of variance; NeuP, neuropathic pain; NoCP, no chronic pain.

In Figure 9 and supplementary Table 6, available at https://links.lww.com/PR9/A186, we present the ORs for a binomial model of NeuP vs non-NeuP. Male participants had a higher OR for NeuP vs non-NeuP. Higher BMI and lower age were associated with an increased OR for NeuP. Most bothersome pain in the feet was associated with increased odds for NeuP, whereas most bothersome pain in the abdomen, shoulder, knee, hip, back, chest, and headache was associated with reduced odds for NeuP. “Personal service occupations” were associated with increased odds for NeuP and “professional occupations” with decreased odds for NeuP.

Figure 9.:
Coefficient estimates of the binomial logit model for the 2 painful groups. Dots represent the exponentiated coefficient estimates, ie, odds ratios, and lines show the 95% confidence interval for all terms with an 1-way ANOVA P value <0.05. Odds ratios are calculated for NeuP against the reference level non-NeuP. The P value is colour coded. ANOVA, analysis of variance; BMI, body mass index; BPI, Brief Pain Inventory; NeuP, neuropathic pain.

4. Discussion

In this large cross-sectional study of middle-aged adults in UK Biobank, the prevalence of NeuP was 9.2%, making up 18.1% of those with chronic pain. The published range of prevalence estimates for NeuP in the general population is 3.2% to 17.9%.9,14,25,32,38,51,54,60–62 In the United Kingdom, 2 studies reported similar prevalences of 8.2%50 and 9.3%,48 respectively. The wide range of prevalences reported is partly due to differences in case ascertainment and definition. In Japan, the relatively low prevalence of 3.2% can be explained by the stringent case definition used.32 In studies that used the same definition as the current one, the prevalence of NeuP was lower in France (6.9%9) and higher in Canada (16.1% and 17.9%51,54) and Morocco (10.6%25), although these studies have a wider age range than the current study.

The main strength of this study is the NeuP sample size (n = 13,747), which is more than 5 times that of the largest previous study in a community-based cohort.14 The usage of validated questionnaires allows for direct comparison with other studies of NeuP, notably DOLORisk27,40 and the Pain in Neuropathy Study (PiNS).47

The current study has enabled the identification of associations with a greater level of precision than previous studies. In addition, unlike some previous studies, we conducted multivariate regression analysis, which enabled us to control for covariates.14,25,32,48,51,61 However, in this study, we have not performed any causal inference or modelling, and as such, results should only be interpreted as associations. First, people with NeuP have worse health-related quality of life than people without NeuP.3,32,49,51 Most studies reporting this finding used only univariate hypothesis tests, which does not control for covariates, such as differing pain intensity,38,62 in contrast to the current study.

Second, this study supports previous findings that pain intensity is more severe in people with NeuP than people with non-NeuP.9,25,32,38,48,50,51,60,62 Part of the possible reason for this is the relative difficulty in treating NeuP. It has previously been reported that significantly fewer people with NeuP rate their prescribed treatment as “very successful.”60

Third, people with NeuP were more likely to report pain in their hands, legs, or feet,9,25,32,50,62 whereas people with non-NeuP were more likely to report pain in their stomach or abdomen, neck or shoulder, knees, hips, head, chest, and back.25,50,62 Common aetiologies of NeuP including diabetes, surgery, carpal tunnel syndrome, complex regional pain syndrome, and cancer often affect the upper and lower extremities. This is supported by the association of these comorbidities independently with NeuP.

In addition to these findings, we identified some novel associations with NeuP. This includes RA. Although arthritis is generally considered to be non-neuropathic in nature, there is growing evidence of a neuropathic component to this cause of pain.17,33,34,45 Furthermore, RA can predispose to NeuP disorders such as carpal tunnel syndrome,58 vasculitic neuropathy,24 and spinal cord compression.15 However, a previous study found no association with NeuP.22 But, as individuals can suffer from pain in multiple locations, it is possible that rheumatoid arthritis could be present in a person with NeuP in another location with a different cause.

Another novel finding of this study is that BMI was significantly higher in people with NeuP than in people with non-NeuP. Despite not being previously reported in a community-based cohort, this association has been reported in specific populations with NeuP including diabetic peripheral neuropathy44 and rheumatoid arthritis.33 Higher BMI is associated with increased risk of common conditions causing NeuP including diabetes57 and cardiovascular disease,37 whereas obesity can place increased strain on the joints, exacerbating painful symptoms in rheumatoid arthritis.4

Male sex was associated with increased risk of having NeuP vs non-NeuP, whereas female sex was associated with increased risk of having NeuP vs NoCP. Female sex has been consistently associated with NeuP when compared with non-NeuP in the literature, in both adjusted9,50,60,62 and unadjusted analysis.25,48,51 A notable exception is a Canadian study, which also used the DN4.54

Younger age was significantly associated with NeuP. Previous studies, mostly analysing age as a categorical variable, found that NeuP is more prevalent in older people,9,25,32,50,54 although some have reported no association.48,51,60 A study conducted in France identified a peak prevalence of NeuP in the 50- to 64-year age group.9 As the age range of the cohort for the current study was 49 to 83 years (Q1 = 61, Q3 = 73) at the time of completing the chronic pain phenotyping survey, the age group expected to have the higher prevalence of NeuP were amongst the younger participants. This could explain these findings.

Being in a personal service, skilled trade, or plant and machine operative job and not being in a professional occupation were associated with NeuP. A previous study in France found that NeuP was significantly more prevalent in manual workers, farmers, retirees, and other nonworking people, compared with those in managerial positions.9 These are occupations in which people are likely to require repetitive use of hands and feet, which could make nerve damage more likely.

This study also has some limitations. Our definition of NeuP relies on a self-completed screening tool for NeuP, which does not meet the grading system for “probable” or “definite” NeuP,19 because clinical examination is clearly not feasible in a population survey.

The study was cross-sectional; thus, it was not possible to determine whether the relationships between NeuP and the independent variables reported are causal.31 Moreover, demographic and socioeconomic data were only collected during recruitment and are not concurrent with pain phenotyping. However, there are currently plans for UK Biobank to repeat the chronic pain survey in 2023 presenting an opportunity for future longitudinal studies.

Similarly, future studies will explore the wealth of genetic data within UK Biobank to validate recent findings and to potentially identify novel associations.55,56

A further weakness of the study is that the UK Biobank had a very low initial response rate, is limited to white middle- to old-aged adults and underrepresents people from more socioeconomically deprived areas, as well as people who are obese, smoke, drink alcohol, and self-report certain health conditions. It may also suffer from “healthy volunteer” bias.21 However, this should not make the exposure-disease associations not generalisable.21 Because NeuP has previously been associated with these health-related states, our estimate of the prevalence of NeuP may be conservative.10,33,39,44 We also found an overrepresentation of females, younger age, lower BMI, and less social deprivation in those participating in the pain phenotyping survey compared with those who did not participate, suggesting an element of ascertainment bias. However, it should be noted that although these observations reached significance statistically, this may reflect the fact that the study was highly powered to detect even small differences between groups.

In conclusion, this study represents the largest epidemiological study of NeuP to date and confirms that the disorder is common and places a significantly greater burden on people compared with those without the disorder. In addition, it has identified demographics and clinical characteristics that increase the risk of having chronic NeuP, some of which may be amenable to targeted prevention. These findings will be of particular interest to health care professionals who will be able to influence clinical policy for preventing and treating the disorder.


The authors have no conflict of interest to declare.

Appendix A. Supplemental digital content

Supplemental digital content associated with this article can be found online at https://links.lww.com/PR9/A186.


Supported by Diabetes UK under grant agreement 19/0005984, the European Union's Horizon 2020 research and innovation programme under grant agreement No 633491 (DOLORisk) and the MRC and Versus Arthritis funding to the PAINSTORM consortium as part of the Advanced Pain Discovery Platform (MR/W002388/1). No funding body had any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. A. C. Themistocleous is supported by Academy of Medical Sciences Starter Grant SGL022\1086 and is a Honorary Senior Research Fellow and Carnegie-Wits Diaspora Fellow at the Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg. D. L. H. Bennett and G. Baskozos are supported by the Wellcome Trust, grant reference 223149/Z/21/Z.

Ethics: Data for this study were obtained from the UK Biobank for project “Risk factors for chronic pain,” Application ID: 49572. UK Biobank has approval from the North West Multicentre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval, REC reference: 21/NW/0157, IRAS project ID: 299116. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval.


[1]. Abbott CA, Malik RA, Van Ross ERE, Kulkarni J, Boulton AJM. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220–4.
[2]. Aslam A, Singh J, Rajbhandari S. Prevalence of painful diabetic neuropathy using the self-completed Leeds assessment of neuropathic symptoms and signs questionnaire in a population with diabetes. Can J Diabetes 2015;39:285–95.
[3]. Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. PAIN 2011;152:2836–43.
[4]. Bae S-C, Lee YH, Lee H, Lee YH. Causal association between body mass index and risk of rheumatoid arthritis: a Mendelian randomization study. Eur J Clin Invest 2019;49:e13076.
[5]. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 2005;6:149–58.
[6]. Biobank UK. Pain web questionnaire version 2.0, 2021. Available at: https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/pain_questionnaire.pdf. Accessed April 12, 2022.
[7]. Blyth FM. Global burden of neuropathic pain. PAIN 2018;159:614–7.
[8]. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). PAIN 2005;114:29–36.
[9]. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. PAIN 2008;136:380–7.
[10]. Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLoS One 2013;8:e74195.
[11]. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap 1994;23:129–38.
[12]. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN. Neuropathic pain. Nat Rev Dis Primers 2017;3:17002.
[13]. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518–22.
[14]. DiBonaventura MD, Sadosky A, Concialdi K, Hopps M, Kudel I, Parsons B, Cappelleri JC, Hlavacek P, Alexander AH, Stacey BR, Markman JD, Farrar JT. The prevalence of probable neuropathic pain in the US: results from a multimodal general-population health survey. J Pain Res 2017;10:2525–38.
[15]. Dreyer SJ, Boden SD. Natural history of rheumatoid arthritis of the cervical spine. Clin Orthop Relat Res 1999;366:98–106.
[16]. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281–9.
[17]. Fernandes GS, Valdes AM, Walsh DA, Zhang W, Doherty M. Neuropathic-like knee pain and associated risk factors: a cross-sectional study in a UK community sample. Arthritis Res Ther 2018;20:215.
[18]. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162–73.
[19]. Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice ASC, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: an updated grading system for research and clinical practice. PAIN 2016;157:1599–606.
[20]. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911–20.
[21]. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. Am J Epidemiol 2017;186:1026–34.
[22]. Garip Y, Eser F, Kiliçarslan A, Bodur H. Prevalence of neuropathic pain in rheumatic disorders: association with disease activity, functional status and quality of life. Arch Rheumatol 2015;30:231–7.
[23]. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–858.
[24]. Gwathmey KG, Burns TM, Collins MP, Dyck PJB. Vasculitic neuropathies. Lancet Neurol 2014;13:67–82.
[25]. Harifi G, Amine M, Ait Ouazar M, Boujemaoui A, Ouilki I, Rekkab I, Belkhou A, El Bouchti I, Niamane R, El Hassani S. Prevalence of chronic pain with neuropathic characteristics in the Moroccan general population: a national survey. Pain Med 2013;14:287–92.
[26]. Hébert HL, Colvin LA, Smith BH. The impact of gabapentinoid and opioid prescribing practices on drug deaths: an epidemiological perspective. Pain Manag 2022;12:397–400.
[27]. Hébert HL, Veluchamy A, Baskozos G, Fardo F, Van Ryckeghem DML, Pascal MMV, Jones C, Milburn K, Pearson ER, Crombez G, Bennett DLH, Meng W, Palmer CNA, Smith BH. Cohort profile: DOLORisk Dundee: a longitudinal study of chronic neuropathic pain. BMJ Open 2021;11:e042887.
[28]. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. PAIN 2014;155:654–62.
[29]. van Hecke O, Kamerman PR, Attal N, Baron R, Bjornsdottir G, Bennett DLH, Bennett MI, Bouhassira D, Diatchenko L, Freeman R, Freynhagen R, Haanpää M, Jensen TS, Raja SN, Rice ASC, Seltzer Z, Thorgeirsson TE, Yarnitsky D, Smith BH. Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations. PAIN 2015;156:2337–53.
[30]. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.
[31]. Imagama S, Ando K, Kobayashi K, Nakashima H, Seki T, Hamada T, MacHino M, Ota K, Tanaka S, Morozumi M, Kanbara S, Ito S, Ishiguro N, Hasegawa Y. Risk factors for neuropathic pain in middle-aged and elderly people: a five-year longitudinal cohort in the Yakumo study. Pain Med 2020;21:1604–10.
[32]. Inoue S, Taguchi T, Yamashita T, Nakamura M, Ushida T. The prevalence and impact of chronic neuropathic pain on daily and social life: a nationwide study in a Japanese population. Eur J Pain 2017;21:727–37.
[33]. Ito S, Kobayashi D, Murasawa A, Narita I, Nakazono K. An analysis of the neuropathic pain components in rheumatoid arthritis patients. Intern Med 2018;57:479–85.
[34]. Koop SMW, ten Klooster PM, Vonkeman HE, Steunebrink LMM, van de Laar MAFJ. Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis. Arthritis Res Ther 2015;17:237.
[35]. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–13.
[36]. Krupp LB, Larocca NG, Muir Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–3.
[37]. Larsson SC, Bäck M, Rees JMB, Mason AM, Burgess S. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. Eur Heart J 2020;41:221–6.
[38]. De Moraes Vieira ÉB, Garcia JBS, Da Silva AAM, Mualem Araújo RLT, Jansen RCS. Prevalence, characteristics, and factors associated with chronic pain with and without neuropathic characteristics in São Luís, Brazil. J Pain Symptom Manage 2012;44:239–51.
[39]. Parruti G, Tontodonati M, Rebuzzi C, Polilli E, Sozio F, Consorte A, Agostinone A, Di Masi F, Congedo G, D'Antonio D, Granchelli C, D'Amario C, Carunchio C, Pippa L, Manzoli L, Volpi A. Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy. BMC Med 2010;8:58.
[40]. Pascal MMV, Themistocleous AC, Baron R, Binder A, Bouhassira D, Crombez G, Finnerup NB, Gierthmühlen J, Granovsky Y, Groop L, Hebert HL, Jensen TS, Johnsen K, McCarthy MI, Meng W, Palmer CNA, Rice ASC, Serra J, Solà R, Yarnitsky D, Smith BH, Attal N, Bennett DLH. DOLORisk: study protocol for a multi-centre observational study to understand the risk factors and determinants of neuropathic pain. Wellcome Open Res 2019;3:63.
[41]. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, Deary IJ, MacIntyre DJ, Campbell H, McGilchrist M, Hocking LJ, Wisely L, Ford I, Lindsay RS, Morton R, Palmer CNA, Dominiczak AF, Porteous DJ, Morris AD. Cohort profile: generation Scotland: Scottish family health study (GS: SFHS). The study, its participants and their potential for genetic research on health and illness. Int J Epidemiol 2013;42:689–700.
[42]. Smith BH, Campbell H, Blackwood D, Connell J, Connor M, Deary IJ, Dominiczak AF, Fitzpatrick B, Ford I, Jackson C, Haddow G, Kerr S, Lindsay R, McGilchrist M, Morton R, Murray G, Palmer CNA, Pell JP, Ralston SH, St Clair D, Sullivan F, Watt G, Wolf R, Wright A, Porteous D, Morris AD. Generation Scotland: the Scottish family health study; a new resource for researching genes and heritability. BMC Med Genet 2006;7:74.
[43]. Smith BH, Hébert HL, Veluchamy A. Neuropathic pain in the community: prevalence, impact, and risk factors. PAIN 2020;161(suppl 1):S127–37.
[44]. Spallonel V, Morganti R, D'Amato C, Cacciotti L, Fedele T, Maiello MR, Marfia G. Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function. Eur J Pain 2011;15:153–60.
[45]. Stocks J, Tang NK, Walsh DA, Warner SC, Harvey HL, Jenkins W, Abhishek A, Doherty M, Valdes AM. Bidirectional association between disturbed sleep and neuropathic pain symptoms: a prospective cohort study in post-total joint replacement participants. J Pain Res 2018;11:1087–93.
[46]. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12:e1001779.
[47]. Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D, Orengo C, Tesfaye S, Rice ASC, Bennett DLH. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. PAIN 2016;157:1132–45.
[48]. Torrance N, Ferguson JA, Afolabi E, Bennett MI, Serpell MG, Dunn KM, Smith BH. Neuropathic pain in the community: more under-treated than refractory? PAIN 2013;154:690–9.
[49]. Torrance N, Lawson KD, Afolabi E, Bennett MI, Serpell MG, Dunn KM, Smith BH. Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter? PAIN 2014;155:1996–2004.
[50]. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281–9.
[51]. Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med 2009;10:918–29.
[52]. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630–5.
[53]. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Korwisi B, Kosek E, Lavand'Homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). PAIN 2019;160:19–27.
[54]. VanDenKerkhof EG, Mann EG, Torrance N, Smith BH, Johnson A, Gilron I. An epidemiological study of neuropathic pain symptoms in Canadian adults. Pain Res Manag 2016;2016:1–13.
[55]. Veluchamy A, Hébert HL, Meng W, Palmer CNA, Smith BH. Systematic review and meta-analysis of genetic risk factors for neuropathic pain. PAIN 2018;159:825–48.
[56]. Veluchamy A, Hébert HL, Van Zuydam NR, Pearson ER, Campbell A, Hayward C, Meng W, McCarthy MI, Bennett DLH, Palmer CNA, Smith BH. Association of genetic variant at chromosome 12q23.1 with neuropathic pain susceptibility. JAMA Netw Open 2021;4:e2136560.
[57]. Wainberg M, Mahajan A, Kundaje A, McCarthy MI, Ingelsson E, Sinnott-Armstrong N, Rivas MA. Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: a Mendelian randomization study. PLoS Med 2019;16:e1002982.
[58]. Wiberg A, Smillie RW, Dupré S, Schmid AB, Bennett DL, Furniss D. Replication of epidemiological associations of carpal tunnel syndrome in a UK population-based cohort of over 400,000 people. J Plast Reconstr Aesthet Surg 2022;75:1034–40.
[59]. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600–10.
[60]. Wong SSC, Choi SW, Cheung CW. A comparison of chronic pain with and without neuropathic characteristics in a Hong Kong Chinese population: an analysis of pain related outcomes and patient help seeking behaviour. PLoS One 2018;13:e0204054.
[61]. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med 2009;10:586–93.
[62]. Zghoul N, Ross EL, Edwards RR, Ahmed A, Jamison RN. Prevalence of chronic pain with neuropathic characteristics: a randomized telephone survey among medical center patients in Kuwait. J Pain Res 2017;10:679–87.

Neuropathic pain; General population; Prevalence; Risk factors; UK Biobank; Epidemiology

Supplemental Digital Content

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.